vs
Side-by-side financial comparison of Protalix BioTherapeutics, Inc. (PLX) and Spire Global, Inc. (SPIR). Click either name above to swap in a different company.
Spire Global, Inc. is the larger business by last-quarter revenue ($15.8M vs $9.1M, roughly 1.7× Protalix BioTherapeutics, Inc.). Protalix BioTherapeutics, Inc. runs the higher net margin — -60.3% vs -176.6%, a 116.3% gap on every dollar of revenue. On growth, Spire Global, Inc. posted the faster year-over-year revenue change (-26.9% vs -49.9%). Protalix BioTherapeutics, Inc. produced more free cash flow last quarter ($1.6M vs $-16.2M). Over the past eight quarters, Protalix BioTherapeutics, Inc.'s revenue compounded faster (-6.7% CAGR vs -32.6%).
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
Spire Global, Inc. is a space-to-cloud data and analytics company that specializes in the tracking of global data sets powered by a large constellation of nanosatellites, such as the tracking of maritime, aviation and weather patterns.
PLX vs SPIR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.1M | $15.8M |
| Net Profit | $-5.5M | $-28.0M |
| Gross Margin | 49.4% | 40.2% |
| Operating Margin | -51.1% | -164.1% |
| Net Margin | -60.3% | -176.6% |
| Revenue YoY | -49.9% | -26.9% |
| Net Profit YoY | -184.8% | 42.7% |
| EPS (diluted) | $-0.06 | $-0.85 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.1M | $15.8M | ||
| Q3 25 | $17.9M | $12.7M | ||
| Q2 25 | $15.7M | $19.2M | ||
| Q1 25 | $10.1M | $23.9M | ||
| Q4 24 | $18.2M | $21.7M | ||
| Q3 24 | $18.0M | $28.6M | ||
| Q2 24 | $13.5M | $25.4M | ||
| Q1 24 | — | $34.8M |
| Q4 25 | $-5.5M | $-28.0M | ||
| Q3 25 | $2.4M | $-19.7M | ||
| Q2 25 | $164.0K | $119.6M | ||
| Q1 25 | $-3.6M | $-20.7M | ||
| Q4 24 | $6.5M | $-48.8M | ||
| Q3 24 | $3.2M | $-12.5M | ||
| Q2 24 | $-2.2M | $-16.6M | ||
| Q1 24 | — | $-25.5M |
| Q4 25 | 49.4% | 40.2% | ||
| Q3 25 | 53.4% | 36.6% | ||
| Q2 25 | 62.5% | 48.9% | ||
| Q1 25 | 19.1% | 36.8% | ||
| Q4 24 | 78.7% | 32.4% | ||
| Q3 24 | 53.4% | 44.5% | ||
| Q2 24 | 29.8% | 43.0% | ||
| Q1 24 | — | 26.5% |
| Q4 25 | -51.1% | -164.1% | ||
| Q3 25 | 11.9% | -166.1% | ||
| Q2 25 | 7.5% | -122.7% | ||
| Q1 25 | -41.0% | -106.5% | ||
| Q4 24 | 39.6% | -144.1% | ||
| Q3 24 | 22.2% | -48.0% | ||
| Q2 24 | -18.0% | -48.6% | ||
| Q1 24 | — | -34.4% |
| Q4 25 | -60.3% | -176.6% | ||
| Q3 25 | 13.2% | -155.3% | ||
| Q2 25 | 1.0% | 623.4% | ||
| Q1 25 | -35.8% | -86.5% | ||
| Q4 24 | 35.6% | -225.2% | ||
| Q3 24 | 18.0% | -43.7% | ||
| Q2 24 | -16.4% | -65.2% | ||
| Q1 24 | — | -73.3% |
| Q4 25 | $-0.06 | $-0.85 | ||
| Q3 25 | $0.03 | $-0.61 | ||
| Q2 25 | $0.00 | $3.72 | ||
| Q1 25 | $-0.05 | $-0.77 | ||
| Q4 24 | $0.10 | $-1.93 | ||
| Q3 24 | $0.03 | $-0.50 | ||
| Q2 24 | $-0.03 | $-0.68 | ||
| Q1 24 | — | $-1.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.7M | $81.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $48.2M | $112.9M |
| Total Assets | $82.3M | $211.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.7M | $81.8M | ||
| Q3 25 | $13.6M | $96.8M | ||
| Q2 25 | $17.9M | $117.6M | ||
| Q1 25 | $19.5M | $35.9M | ||
| Q4 24 | $19.8M | $19.2M | ||
| Q3 24 | $27.4M | $36.6M | ||
| Q2 24 | $23.4M | $45.8M | ||
| Q1 24 | — | $63.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $103.7M | ||
| Q4 24 | — | $103.1M | ||
| Q3 24 | — | $4.9M | ||
| Q2 24 | — | $4.9M | ||
| Q1 24 | — | $123.1M |
| Q4 25 | $48.2M | $112.9M | ||
| Q3 25 | $52.9M | $133.1M | ||
| Q2 25 | $49.9M | $149.2M | ||
| Q1 25 | $45.2M | $3.7M | ||
| Q4 24 | $43.2M | $-11.7M | ||
| Q3 24 | $32.4M | $30.8M | ||
| Q2 24 | $28.6M | $40.3M | ||
| Q1 24 | — | $52.5M |
| Q4 25 | $82.3M | $211.0M | ||
| Q3 25 | $82.3M | $224.3M | ||
| Q2 25 | $78.5M | $239.5M | ||
| Q1 25 | $73.9M | $208.8M | ||
| Q4 24 | $73.4M | $193.6M | ||
| Q3 24 | $61.6M | $224.2M | ||
| Q2 24 | $91.5M | $230.8M | ||
| Q1 24 | — | $252.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 27.92× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | 0.12× | ||
| Q1 24 | — | 2.35× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.0M | $-4.3M |
| Free Cash FlowOCF − Capex | $1.6M | $-16.2M |
| FCF MarginFCF / Revenue | 17.8% | -102.1% |
| Capex IntensityCapex / Revenue | 4.4% | 75.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-13.6M | $-92.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | $-4.3M | ||
| Q3 25 | $-3.7M | $-12.0M | ||
| Q2 25 | $-5.2M | $-35.1M | ||
| Q1 25 | $-5.1M | $-8.4M | ||
| Q4 24 | $4.0M | $-19.2M | ||
| Q3 24 | $4.1M | $14.0M | ||
| Q2 24 | $-3.6M | $-4.4M | ||
| Q1 24 | — | $-8.8M |
| Q4 25 | $1.6M | $-16.2M | ||
| Q3 25 | $-4.2M | $-20.4M | ||
| Q2 25 | $-5.7M | $-38.7M | ||
| Q1 25 | $-5.4M | $-17.3M | ||
| Q4 24 | $3.6M | $-24.3M | ||
| Q3 24 | $4.0M | $5.1M | ||
| Q2 24 | $-3.8M | $-9.9M | ||
| Q1 24 | — | $-15.9M |
| Q4 25 | 17.8% | -102.1% | ||
| Q3 25 | -23.7% | -161.3% | ||
| Q2 25 | -36.2% | -201.7% | ||
| Q1 25 | -53.0% | -72.6% | ||
| Q4 24 | 19.6% | -112.2% | ||
| Q3 24 | 22.4% | 17.8% | ||
| Q2 24 | -28.1% | -39.0% | ||
| Q1 24 | — | -45.7% |
| Q4 25 | 4.4% | 75.1% | ||
| Q3 25 | 2.8% | 66.2% | ||
| Q2 25 | 2.8% | 18.8% | ||
| Q1 25 | 3.0% | 37.3% | ||
| Q4 24 | 2.3% | 23.5% | ||
| Q3 24 | 0.5% | 31.2% | ||
| Q2 24 | 1.3% | 21.8% | ||
| Q1 24 | — | 20.3% |
| Q4 25 | — | — | ||
| Q3 25 | -1.58× | — | ||
| Q2 25 | -31.91× | -0.29× | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.61× | — | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
SPIR
Segment breakdown not available.
